Meropenem/vaborbactam-based combinations against KPC-producing Klebsiella pneumoniae and multidrug-resistant Pseudomonas aeruginosa

Int J Antimicrob Agents. 2020 Aug;56(2):106066. doi: 10.1016/j.ijantimicag.2020.106066. Epub 2020 Jun 27.

Authors

Marco Iannaccone¹, Matteo Boattini², Gabriele Bianco², Rossana Cavallo², Cristina Costa²

Affiliations

¹ Microbiology and Virology Unit, University Hospital Città della Salute e della Scienza di Torino, Corso Bramante 88/90, 10126 Turin, Italy. Electronic address: marco.iannaccone@unito.it.
² Microbiology and Virology Unit, University Hospital Città della Salute e della Scienza di Torino, Corso Bramante 88/90, 10126 Turin, Italy.

PMID: 32599226
DOI: 10.1016/j.ijantimicag.2020.106066

No abstract available

Publication types

Letter

MeSH terms

Anti-Bacterial Agents / therapeutic use*
Bacterial Proteins / metabolism
Boronic Acids / therapeutic use*
Drug Combinations
Drug Resistance, Multiple, Bacterial
Drug Synergism
Humans
Klebsiella Infections / drug therapy
Klebsiella pneumoniae / drug effects*
Meropenem / therapeutic use*
Microbial Sensitivity Tests
Pseudomonas Infections / drug therapy
Pseudomonas aeruginosa / drug effects*
beta-Lactamases / metabolism

Substances

Anti-Bacterial Agents
Bacterial Proteins
Boronic Acids
Drug Combinations
vaborbactam
beta-Lactamases
carbapenemase
Meropenem